Assignee
IO BIOTECH APS
DK·15 granted patents·18 pending applications·17 citations·filing 2016–2025
Top patents by PatentIndex Score
33 records- 0194US11447537B2PDL2 compoundsIO BIOTECH APS·Filed 2020·Granted Sep 20, 2022·3 cites·8 claims
- 0294US10858642B2Immunogenic arginase peptidesIO BIOTECH APS·Filed 2017·Granted Dec 8, 2020·7 cites·29 claims
- 0391US11648302B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2022·Granted May 16, 2023·1 cites·19 claims
- 0488US11298413B2Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereofIO BIOTECH APS·Filed 2016·Granted Apr 12, 2022·3 cites·5 claims
- 0586US11981944B2Immunogenic arginase peptidesIO BIOTECH APS·Filed 2020·Granted May 14, 2024·1 cites·13 claims
- 0685US12233103B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2023·Granted Feb 25, 2025·0 cites·19 claims
- 0785US11324813B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2019·Granted May 10, 2022·1 cites·18 claims
- 0885US2025236658A1Pdl2 compoundsIO BIOTECH APS·Filed 2024·Application pending·0 cites
- 0981US12215135B2PDL2 compoundsIO BIOTECH APS·Filed 2022·Granted Feb 4, 2025·0 cites·18 claims
- 1081US2025230218A1Pdl1 peptides for use in cancer vaccinesIO BIOTECH APS·Filed 2024·Application pending·0 cites
- 1179US12187782B2PDL1 peptides for use in cancer vaccinesIO BIOTECH APS·Filed 2022·Granted Jan 7, 2025·0 cites·5 claims
- 1278US12496333B2Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereofIO BIOTECH APS·Filed 2022·Granted Dec 16, 2025·0 cites·14 claims
- 1378US2024167013A1Immunogenic arginase peptidesIO BIOTECH APS·Filed 2023·Application pending·0 cites
- 1478US2022202922A1Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2022·Application pending·0 cites
- 1577US2025205318A1Arginase1 polypeptidesIO BIOTECH APS·Filed 2024·Application pending·0 cites
- 1676US12551543B2Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereofIO BIOTECH APS·Filed 2022·Granted Feb 17, 2026·0 cites·4 claims
- 1775US10258678B2Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2016·Granted Apr 16, 2019·1 cites·13 claims
- 1875US2025319159A1Indoleamine 2,3-dioxygenase based immunotherapyIO BIOTECH APS·Filed 2025·Application pending·0 cites
- 1974US2024052053A1Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)IO BIOTECH APS·Filed 2023·Application pending·0 cites
- 2073US12234288B2Immunogenic arginase 2 polypeptidesIO BIOTECH APS·Filed 2019·Granted Feb 25, 2025·0 cites·7 claims
- 2172US12194081B2ARGINASE1 polypeptidesIO BIOTECH APS·Filed 2019·Granted Jan 14, 2025·0 cites·8 claims
- 2266US2025161422A1Arginase 2 vaccineIO BIOTECH APS·Filed 2023·Application pending·0 cites
- 2365US11878053B2Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereofIO BIOTECH APS·Filed 2020·Granted Jan 23, 2024·0 cites·6 claims
- 2465US2022257741A1Combination therapy for cancerIO BIOTECH APS·Filed 2021·Application pending·0 cites
- 2559US2025388674A1Immunogenic arginase 2 polypeptidesIO BIOTECH APS·Filed 2025·Application pending·0 cites
- 2657US2020024324A1New pdl2 compoundsIO BIOTECH APS·Filed 2017·Application pending·0 cites
- 2755US2020299401A1Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc)IO BIOTECH APS·Filed 2018·Application pending·0 cites
- 2855US2024307516A1Combination therapy for cancerIO BIOTECH APS·Filed 2021·Application pending·0 cites
- 2955US2019343940A1Combination therapy against cancerIO BIOTECH APS·Filed 2017·Application pending·0 cites
- 3052US2020339659A1Pdl1 peptides for use in cancer vaccinesIO BIOTECH APS·Filed 2017·Application pending·0 cites
- 3149US2025327041A1Nucleotide delivery of cancer therapyIO BIOTECH APS·Filed 2023·Application pending·0 cites
- 3249US2022315634A1Tgf-beta vaccineIO BIOTECH APS·Filed 2020·Application pending·0 cites
- 3340US2019328857A1Calr and jak2 vaccine compositionsIO BIOTECH APS·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →